Not available
Quote | Silence Therapeutics Ord (OTCMKTS:SLNCF)
Last: | $7.60 |
---|---|
Change Percent: | -21.43% |
Open: | $8.5 |
Close: | $7.60 |
High: | $8.5 |
Low: | $7.5 |
Volume: | 2,020 |
Last Trade Date Time: | 07/18/2024 03:00:00 am |
News | Silence Therapeutics Ord (OTCMKTS:SLNCF)
Divesiran eliminated the need for phlebotomy in all well-controlled patients following infrequent dosing and was well tolerated Data support advancing divesiran into Phase 2 Company to host conference call today at 8:30am Eastern Time Silence Therapeutics plc (“Si...
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming peoples’ lives by silencing diseases through precision engineered medicines, today announced that it will receive a ...
Message Board Posts | Silence Therapeutics Ord (OTCMKTS:SLNCF)
Subject | By | Source | When |
---|---|---|---|
Emylers: SLNCF Financials 07/16/2014 14:39:30 Silence Therapeutics, Plc. Period Ending Total Revenue | Emylers | investorshangout | 07/16/2014 7:39:26 PM |
Silence Therapeutics plc Rating Reiterated by Canaccord Genuity (SLN) | Wildbilly | investorshub | 03/12/2014 5:26:04 PM |
Silence Therapeutics A Quieter Name In RNAi | Wildbilly | investorshub | 03/12/2014 5:18:37 PM |
Stock_Tracker: Latest Silence Therapeutics (SLNCF) Headlines Global RNAi Drug Delivery Market 2014-2 | Stock_Tracker | investorshangout | 03/11/2014 1:26:09 PM |
chartguy89: SLNCF 6.30 Stock Charts $SLNCF 1 Month Chart | chartguy89 | investorshangout | 03/10/2014 1:16:26 AM |
News, Short Squeeze, Breakout and More Instantly...
Silence Therapeutics Ord Company Name:
SLNCF Stock Symbol:
OTCMKTS Market:
Silence Therapeutics Ord Website:
Divesiran eliminated the need for phlebotomy in all well-controlled patients following infrequent dosing and was well tolerated Data support advancing divesiran into Phase 2 Company to host conference call today at 8:30am Eastern Time Silence Therapeutics plc (“Si...
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming peoples’ lives by silencing diseases through precision engineered medicines, today announced that it will receive a ...
Study demonstrated highly significant and sustained reductions in Lp(a) to week 48 Data support advancing zerlasiran into phase 3 with 300 mg dose Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotec...